Lumicitabine

Lumicitabine
Clinical data
Trade names	Lumicitabine
Legal status
Legal status	US: Investigational New Drug;
Identifiers
	IUPAC name [(2R,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-2-(chloromethyl)-4-fluoro-3-(2-methylpropanoyloxy)oxolan-2-yl]methyl 2-methylpropanoate;
CAS Number	1445385-02-3;
PubChem CID	89658382;
ChemSpider	58171803;
UNII	BNW5PQ52G1;
ECHA InfoCard	100.245.433
Chemical and physical data
Formula	C18H25ClFN3O6
Molar mass	433.86 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)C(=O)OC[C@@]1([C@H]([C@H]([C@@H](O1)N2C=CC(=NC2=O)N)F)OC(=O)C(C)C)CCl;
	InChI InChI=1S/C18H25ClFN3O6/c1-9(2)15(24)27-8-18(7-19)13(28-16(25)10(3)4)12(20)14(29-18)23-6-5-11(21)22-17(23)26/h5-6,9-10,12-14H,7-8H2,1-4H3,(H2,21,22,26)/t12-,13+,14-,18-/m1/s1; Key:MJVKYGMNSQJLIN-KYZVSKTDSA-N;

Lumicitabine (ALS-8176) is an antiviral drug which was developed as a treatment for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). It acts as an RNA polymerase inhibitor.^[1] While it showed promise in early clinical trials,^[2]^[3] poor results in Phase IIb trials led to it being discontinued from development for treatment of RSV.^[4] Research continues to determine whether it may be useful for the treatment of diseases caused by other RNA viruses, and it has been found to show activity against Nipah virus.^[5]